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IntroductIon
Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming 
the most common liver disease worldwide (1). The prevalence 
of NAFLD in the general population is estimated to be 20–30% 
in western countries (2,3) and 15% in Asian countries (4,5). 
Though the prevalence is partly depended on the method used 
to diagnose NAFLD, NAFLD has been undoubtedly an impor-
tant global disease burden not only for its high and fast increas-
ing prevalence, but also for its severe metabolic complications. 
NAFLD associates with insulin resistance, obesity, hyperten-
sion, type 2 diabetes mellitus (T2DM), hyperlipidemia (6,7) and 
may precede T2DM development and cardiovascular disease 
(CVD (8)). Recently, carotid atherosclerosis has been detected 
in patients with NAFLD even with no alterations in liver enzyme 
tests (9). Thus, an accurate assessment of hepatic fat infiltration 
would have profound significance in the clinical setting.
Liver biopsy is the “gold” standard for quantification of 
hepatic steatosis. However, it is hard to be accepted by most 
patients for its invasiveness and a significant degree of sam-
pling error (10). Moreover, most patients with hepatic steatosis 
are asymptomatic (11), and only 50% of patients with NAFLD 
(12) will have elevated alanine transaminases. Therefore, an 
accurate, cost-effective and noninvasive imaging method that 
can quantitatively measure liver fat content is ideally needed.
[1H]-magnetic  resonance  spectroscopy  (MRS)  directly 
measures protons in acyl groups of liver tissue triglycerides 
(13), and the values obtained using [1H]-MRS correlate well 
with the histological liver fat content (14–16), which provides 
an accurate, sensitive, and noninvasive method to quantify 
liver fat content. Our previous study also showed a close posi-
tive correlation between the hepatic triglyceride content by 
[1H]-MRS and pathological measurements of liver fat content 
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(r = 0.878, P < 0.0001 (17)). The “upper limit of normal” for 
hepatic triglyceride content by [1H]-MRS was determined to 
be 5.56% in the Dallas Heart Study (18). However, [1H]-MRS 
is expensive and far less available than other imaging examina-
tions, which limits its use in clinical practice and large-scale 
epidemiological studies.
Ultrasonography (US) is an appealing technique to detect 
fatty infiltration of the liver because of its simplicity, low-cost, 
noninvasive nature, and widespread availability. However, its 
application is limited by the interobserver and intraobserver 
variability (19), poor sensitivity in detecting mild hepatic stea-
tosis (20), and ultimately it is unable to provide an accurate 
measurement of liver fat content. Recently several attempts 
have been made to establish methods for quantitative assess-
ment of liver fat content by US. Edens et al. showed the feasi-
bility of ultrasound liver fat content quantification by using a 
combination of computer-assisted ultrasound measures from 
routine ultrasound images (21). However, these ultrasound 
parameters were obtained with specially developed software 
program and somewhat complex for practical clinical appli-
cation. Meanwhile, studies by Webb et al. (22) and Mancini 
et al. (23) reported that computer-aided measurement of US 
hepatic/renal echo-intensity ratio (H/R) were highly correlated 
with liver fat content determined by histology and [1H]-MRS, 
respectively. These two studies indicated US hepatic/renal ratio 
as a suitable quantitative parameter to quantitatively reflect liver 
fat content, but the value ranges of the US H/R ratios from the 
two studies differed greatly, which were totally not comparable. 
Thus, standardization of the US H/R ratio is necessary before 
its widespread clinical application. In addition, one recent pilot 
study also attempted to use phantom-calibrated, computer-
measured ultrasound hepatic attenuation coefficients to assess 
the severity of hepatic steatosis in dairy cattles (24). However, 
none of these studies has clearly provided a relative accurate, 
stable, and reproducible US quantitative method for liver fat 
content yet.
In this study, we improved the method for US H/R ratio 
and US hepatic echo-intensity attenuation rate (HA) meas-
urement by introducing a tissue-mimicking phantom for 
standardization to make them more comparable among dif-
ferent ultrasound machines. Furthermore, we also attempted 
to establish and validate a predictive algorithm for liver fat 
content with standardized US H/R and HA, using [1H]-MRS 
as standard.
Methods and Procedures
subjects
US and [1H]-MRS examinations were performed in 127 participants 
(age range, 16–75 years; BMI range, 18.2–37.7 kg/m2) who were diag-
nosed with no or different degrees of hepatic steatosis by routine US 
examinations from the outpatient department of endocrinology and 
physical examination center of Zhongshan Hospital, Shanghai, China. 
Of the 127 participants, 35 were diagnosed with no hepatic steatosis, 
64 with mild hepatic steatosis, and 28 with moderate or severe hepatic 
steatosis. The participants did not have a history, clinical symptoms, or 
signs of other liver or renal disease; nor did they have history of diabe-
tes or excess alcoholic drinking (≥20 g/day for men and ≥10 g/day for 
women (25)). They were not taking hypolipidemic drug, liver protect-
ant, or drugs that could cause steatosis. All participants had negative 
hepatitis B virus surface antigen and hepatitis C virus antibody, normal 
renal function, and absence of proteinuria in spot urine collection.
The protocol for the study was approved by the ethics committee of 
Zhongshan Hospital, Shanghai. Written informed consent was obtained 
from all participants.
Anthropometric, ultrasound, and [1H]-MRS measurements were per-
formed at the same day, and fasting venous blood samples were drawn for 
determination of blood routine, liver and renal function, and hepatitis 
virus indication.
anthropometric measurements
The measurement of height and weight required the subjects wore light 
clothing without shoes. Body mass index was calculated as weight (kg) 
divided by height (m) squared. Waist circumference was measured with 
a soft tape on standing subjects midway between the lowest rib and the 
iliac crest. Hip circumference was assessed at the level of the greater 
trochanters. Blood pressure was measured on right arm with subjects 
in a sitting position after a 5-min rest.
Biochemical analysis
Biochemical tests for liver enzymes, serum lipid profile, and fasting 
plasma glucose were performed using an autoanalyzer (Hitachi 7300, 
automatic analyzer, Tokyo, Japan). Serum hepatitis B virus surface 
antigen and hepatitis C virus antibody were tested by the Enhanced 
Electrochemiluminescence method.
us
All examinations were performed with a GE Vivid7 ultrasound machine 
(GE Healthcare, Horten, Norway) equipped with a GE 4C curved array 
transducer (GE H4904PC). Twenty-six of the subjects also accepted a 
second US examination within 12 h on another GE Logiq P5 ultrasound 
machine (GE Healthcare, Milwaukee, WI). US studies were performed 
by two experienced radiologists (WH and CL) who were unaware of 
the patient’s clinical details and laboratory findings. All the instrument 
settings, including “gain,” “depth,” and “time-gain compensation,” were 
fixed for each measurement. For assessment of US H/R ratio, ultrasound 
images with both liver and right kidney clearly visualized were obtained 
in the sagittal liver/right kidney view in the lateral position (Figure 1a). 
US hepatic echo-intensity attenuation rate was assessed in right intercos-
tals view at anterior axilla line in the supine position (Figure 1b).
ultrasound image analysis
All images were transferred to a personal computer and reviewed by 
one of the two radiologists involved in scanning. Analysis of digitized 
ultrasound images was performed by using NIHimage software (ImageJ 
1.41o, National Institutes of Health, Bethesda, MD).
us hepatic/renal echo-intensity ratio
In sagittal liver/right kidney view, a region of interest (ROI) of 1.5 × 
1.5 cm (1,296 pixels) in the liver parenchyma was selected. The ROI had 
to be as uniform as possible, excluding blood vessels, bile ducts, and other 
focal hypo/hyperechogenicity. Another ROI of 0.5 × 0.5 cm (144 pixels) 
was identified in the right renal cortex with no large vessels, renal sinus 
or medulla. To avoid the interference of depth-depended echo-intensity 
attenuation and the borderline echo distorting effects, the boundary 
between liver and right kidney area should be placed near the center 
of the image, and the liver and right kidney ROIs were selected at the 
same depth of the ultrasound images. The gray scale mean value of the 
pixels within the two ROIs was used as measurement of echo intensity 
(Figure 1a). Then we divided the average hepatic gray scale by the aver-
age renal cortex gray scale to calculate the US hepatic/renal ratio.
us hepatic echo-intensity attenuation rate
In right intercostals view at anterior axilla line, a tangent line of 
the sector ultrasound image was drawn and the ultrasound wave 
transmission line was determined, starting from the point of   tangency 446  VOLUME 20 NUMBER 2 | fEBRUaRy 2012 | www.obesityjournal.org
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and perpendicular to the tangent line. Two ROIs of 1.5 × 1.5 cm 
(1,296 pixels) were selected in liver homogeneous regions along the 
ultrasound transmission line near the liver anterior margin (depth 
4–6 cm) and the liver posterior margin, respectively. The linear dis-
tance between the two ROIs was also measured (Figure 1b).
The echo intensity of ultrasound wave was attenuated exponentially, 
shown as the following equation (26,27):
AA
afd
d0 e =×
−⋅⋅  
(1)
Where A0 and Ad are ultrasound echo intensity at the sound source and 
the liver parenchyma at a specific depth, respectively; a is the attenua-
tion coefficient of the liver parenchyma; f is the frequency of the ultra-
sound detector; d is the depth of ROI.
The ratio of the average echo intensity in the liver near-field ROI to 
liver far-field ROI was then calculated based on equation (1):
AA
af fn
nf
dd e =
⋅⋅ − ()  (2)
Where An and Af are average ultrasound echo intensity in the near-field 
ROI and the far-field ROI, respectively; a and f have been defined in 
equation (1); dn and df are the depth of liver near-field and far-field 
ROIs.
Then the formula for ultrasound hepatic echo-intensity attenuation 
rate was deduced from equation (2):
aAAd f = (−)/(⋅ ) ln l n  nf   (3)
Where Δd is the distance between the near-field and far-field ROIs, and 
other parameters are defined in equation (2).
standardization of ultrasound quantitative parameters
To standardize the measured values of US H/R ratio and hepatic echo-
intensity attenuation rate among different ultrasound machines, a 3D 
abdominal phantom (Model 057; Computerized Imaging Reference 
Systems, Norfolk, VA), containing mimic abdominal organs, was used 
for standardization in this research. The ultrasound images of the phan-
tom were obtained under both of the ultrasound machines (GE Vivid7 
and GE Logiq P5), and the phantom’s H/R ratio and hepatic attenuation 
rate were measured with the same protocol for ultrasound image analy-
sis described above. Then we divided the measured ultrasound H/R 
ratios by the phantom’s H/R ratio and subtracted the phantom’s hepatic 
attenuation rate from the patients’ hepatic attenuation rates to obtain 
the standardized US H/R ratio and standardized hepatic attenuation 
rate (Supplementary Figure S1 online).
Validation of ultrasound quantification of liver fat content
To assess the agreement in measuring standardized US H/R and hepatic 
attenuation rate between different operators and different ultrasound 
machines, 26 participants accepted US examinations on two different 
ultrasound machines (GE Vivid7 and GE Logiq P5) by the same radi-
ologist within 12 h, and 23 participants were examined separately by 
two radiologists within 12 h.
Measurement of hepatic triglyceride content using [1h]-Mrs
[1H]-MRS measurements were performed on a 1.5-T magnetic reso-
nance (MR) scanner (Siemens Avanto, Erlangen, Germany) equipped 
for proton spectroscopy acquisitions. Sagittal, coronal, and axial slices 
covering the whole liver were preliminarily acquired for positioning 
of the spectroscopy acquisition voxel. A single voxel of 8 cm3 (2 × 2 × 
2 cm) was placed within the right lobe avoiding major vascular struc-
tures and subcutaneous fat tissue. The proton spectrum was acquired 
using the body coil after shimming over the volume of interest by 
means of a point-resolved spectroscopy (PRESS) sequence with the 
following parameters: repetition time = 1,500 ms, echo time = 135 ms. 
Signal intensities of water peak at 4.8 ppm (Sw) and the fat peak at 
1.4 ppm(Sf) were measured, and hepatic fat percentage was calculated 
using the formula 100 × Sf/(Sf + Sw), as described by our group previ-
ously (28).
statistical analysis
All statistical analyses were performed using SPSS software version 13.0 
(SPSS, Chicago, IL). The data are presented as mean ± s.d. except for skewed 
variables, which are presented as median (interquartile range 25–75%). 
One-way ANOVA was used for comparisons among groups. Multivariate 
linear stepwise regression analysis was used to establish predictive algo-
rithm for liver fat content with the ultrasonic quantitative parameters, 
using  [1H]-MRS  as  standard.  Receiver  operating  characteristic  curve 
analysis was used to determine the appropriate cutoff value for ultrasound-
estimated liver fat content to diagnose NAFLD. The optimal cutoff values 
were obtained from the Youden index (maximum (sensitivity + specificity 
− 1 (29))). Pearson’s correlation analysis was used to explore the associa-
tion of ultrasound liver fat content with all measured metabolism-related 
parameters. Interobserver variation, as well as the variation between differ-
ent ultrasound machines, was assessed using intraclass correlation (ICC) 
coefficient and Bland–Altman statistics (30). Values for P < 0.05 were con-
sidered statistically significant for all analyses.
results
study population
The study population consisted of 71 men and 56 women, 
with an age range of 16–75 year, BMI of 18.2–37.7 kg/m2, and 
waist-to-hip ratio of 0.78–1.12. Liver fat content determined 
by [1H]-MRS analysis ranged from 3.0 to 70.9% (mean 20.2%). 
a
b
6.64 cm
Figure 1  Ultrasound images of liver in (a) sagittal liver/right kidney 
view and (b) right intercostals view in a 53-year-old man show graphic 
representation of region of interest (ROI) rectangles. ROI-1, ROI-2, 
ROI-3, and ROI-4 show the gray scale distribution of the pixels in the 
selected liver, right kidney cortex, liver near-field, and liver far-field 
region, respectively. The linear distance between the top left corners of 
near-field and far-field liver ROIs was also measured.obesity | VOLUME 20 NUMBER 2 | fEBRUaRy 2012  447
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By application of the current criteria for diagnosis of steato-
sis by [1H]-MRS, 81.1% of the subjects (103/127) had a liver 
fat content exceeding 5.56%. The original ultrasound hepatic/
renal ratios and hepatic echo-intensity attenuation rates were 
0.88–2.17 (mean 1.39) and −0.0289/MHz/cm–0.0475/MHz/
cm (mean 0.0146/MHz/cm), respectively. After standardiza-
tion, the hepatic/renal ratios were adjusted to be 0.48–1.19, and 
the adjusted hepatic echo-intensity attenuation rates ranged 
from −0.0409 to 0.0355/MHz/cm (Table 1).
estimation of liver fat content by [1h]-Mrs using us 
quantitative parameters
Both US hepatic/renal ratio and US hepatic attenuation rate 
were highly positively associated with the liver fat content by 
[1H]-MRS, with r = 0.884, (P < 0.001) and r = 0.711, (P < 0.001), 
respectively (Figure 2a,b). Multivariate linear regression analysis 
was performed to investigate main factors associated with liver 
fat content from all common anthropometric and US quanti-
tative parameters. The greatest contribution to the prediction 
table 1  characteristics of the study patients
Characteristic
[1H]-MRS hepatic fat content (%)
<5 5–10 10–20 20–30 ≥30 Total P value*
Number of participants 16 20 27 39 25 127
Age (year) 56(50–58) 52(46–57) 54(49–61) 53(44–59) 52(40–57) 53(44–59) 0.435
Sex (male/female) 4/12 12/8 19/8 21/18 15/10 71/56 0.065
Anthropometric measures
  Weight (kg) 64.9 ± 3.9 74.0 ± 2.9 76.3 ± 1.9 77.5 ± 2.3 79.3 ± 3.2 75.4 ± 1.3 0.015
  Height (cm) 161.7 ± 2.4 165.2 ± 1.8 167.5 ± 1.5 166.0 ± 1.5 167.8 ± 2.0 166.0 ± 0.8 0.226
  BMI (kg/m2) 24.4 ± 0.9 26.7 ± 0.6 27.2 ± 0.5 27.9 ± 0.5 28.0 ± 0.7 27.1 ± 0.3 0.006
  Waist circumference (cm) 82.1 ± 3.0 91.0 ± 2.1 93.8 ± 1.3 95.7 ± 1.5 94.9 ± 1.5 92.6 ± 0.9 <0.001
  Hip circumference (cm) 93.5 ± 1.8 97.3 ± 1.2 97.8 ± 1.2 99.6 ± 1.1 99.6 ± 1.2 98.1 ± 0.6 0.016
  Waist-to-hip ratio 0.88 ± 0.02 0.93 ± 0.01 0.96 ± 0.01 0.96 ± 0.01 0.95 ± 0.01 0.94 ± 0.01 <0.001
  SBP (mm Hg) 129.4 ± 8.2 129.7 ± 2.9 137.2 ± 3.0 139.5 ± 4.2 132.7 ± 3.3 134.6 ± 1.9 0.365
  DBP (mm Hg) 71.9 ± 4.2 77.8 ± 1.9 82.7 ± 2.3 83.0 ± 1.8 82.6 ± 2.0 80.6 ± 1.1 0.013
Liver enzymes
  ALT (IU/l) 17 (12–20) 18 (14–25) 28 (19–45) 34 (21–60) 42 (33–85) 28 (18–50) <0.001
  AST (IU/l) 19 (15–23) 19 (18–23) 23 (18–27) 24 (17–40) 32 (23–40) 23 (18–30) 0.001
  ALP (IU/l) 64.4 ± 4.1 72.9 ± 4.5 79.4 ± 3.9 72.1 ± 2.5 76.3 ± 5.7 73.7 ± 1.9 0.230
  γ-GT (IU/l) 20 (12–37) 30 (23–50) 28 (22–69) 35 (22–57) 51 (28–61) 34 (22–57) 0.013
Lipid profile
  Triglycerides (mmol/l) 1.04  
(0.76–1.29)
1.36  
(0.98–1.60)
1.95  
(1.29–2.61)
1.99  
(1.43–2.40)
1.72  
(1.45–2.50)
1.61  
(1.18–2.36)
<0.001
  Cholesterol (mmol/l) 4.95 ± 0.31 4.99 ± 0.21 4.88 ± 0.20 5.19 ± 0.18 5.06 ± 0.19 5.03 ± 0.09 0.831
  HDL cholesterol (mmol/l) 1.43 ± 0.07 1.22 ± 0.05 1.18 ± 0.05 1.21 ± 0.05 1.13 ± 0.03 1.22 ± 0.02 0.003
  LDL cholesterol (mmol/l) 3.00 ± 0.27 3.14 ± 0.15 2.80 ± 0.17 2.99 ± 0.14 2.87 ± 0.13 2.95 ± 0.07 0.682
  Apo-A (g/l) 1.48 ± 0.07 1.29 ± 0.08 1.29 ± 0.05 1.34 ± 0.06 1.28 ± 0.04 1.33 ± 0.03 0.241
  Apo-B (g/l) 0.91 ± 0.06 1.05 ± 0.05 1.06 ± 0.05 1.12 ± 0.04 1.09 ± 0.04 1.06 ± 0.02 0.059
  Apo-E (mg/dl) 37 (30–42) 36 (30–42) 42 (35–52) 45 (38–57) 47 (38–53) 41 (36–50) 0.003
  Uric Acid (umol/l) 296.3 ± 23.8 339.3 ± 18.3 349.6 ± 15.9 343.2 ± 13.7 363.0 ± 20.8 341.9 ± 8.1 0.207
Blood glucose
  Fasting glucose (mmol/l) 5.2 (4.6–6.4) 5.6 (5.2–6.0) 6.1 (5.2–6.7) 6.2 (5.4–7.3) 6.0 (5.5–6.9) 5.9 (5.3–6.7) 0.056
  2-h postload glucose (mmol/l) 7.1 ± 0.7 8.1 ± 1.1 11.0 ± 0.8 11.3 ± 0.8 10.5 ± 0.8 10.0 ± 0.4 0.003
US measures (standardized)
  Hepatic/renal ratio 0.56 ± 0.01 0.62 ± 0.02 0.72 ± 0.02 0.81 ± 0.08 0.97 ± 0.02 0.76 ± 0.01 <0.001
  Hepatic attenuation rate  
  (cm−1·MHz−1)
−0.0194  
± 0.0032
−0.0069  
± 0.0022
0.0027  
± 0.0017
0.0074  
± 0.0017
0.0169  
± 0.0019
0.0027  
± 0.0013
<0.001
Data are mean ± s.e.m. or median (interquartile range) for continuous variables.
DBP, diastolic blood pressure; HDL, high-density lipoprotein; [1H]-MRS, proton magnetic resonance spectrum; LDL, low-density lipoprotein; SBP, systolic blood pressure. 
*P values for the overall comparisons among groups with different hepatic fat content.448  VOLUME 20 NUMBER 2 | fEBRUaRy 2012 | www.obesityjournal.org
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of liver fat content came from the US H/R ratio, and it could 
be used independently to calculate liver fat content (adjusted 
explained variance to 78.0%, P < 0.001). (Model 1, Table 2). The 
addition of US hepatic attenuation rate to the US hepatic/renal 
ratio further improved the explained variance in liver fat con-
tent from 78.0 to 79.8%. This was reflected in the 4.2% reduction 
in root mean squared error. (Model 2, Table 2). The algorithm 
derived from the second predictive model was as follows:
Liver fat content (%) = 62.592 × US hepatic/renal ratio + 
168.076 × US hepatic attenuation rate − 27.863
Quantitative vs. qualitative us
Validity of the above ultrasound quantitative algorithm, in 
comparison with a qualitative US method used in clinical care, 
is shown in Table 3. Patients with liver fat content measured by 
[1H]-MRS of at least 5.56% were diagnosed as hepatic steatosis. 
Receiver operating characteristic curve analysis showed that 
the optimal cutoff value for ultrasound-estimated liver fat con-
tent to diagnose hepatic steatosis was 9.15%. Using cutoff value 
of 9.15%, the sensitivity and specificity for quantitative US to 
diagnose hepatic steatosis were 95.1% and 100%, respectively, 
better than the qualitative US, whose sensitivity and specifi-
city were 82.5 and 83.3%, respectively. In the 63 subjects with 
liver fat content by [1H]-MRS less than 15%, the quantitative 
US also yielded very high sensitivity (82.6%) and specificity 
(100%), but the sensitivity and specificity of traditional US 
were only 47.8 and 83.3%, respectively (Table 3).
correlation between ultrasound-estimated liver fat content 
and all other metabolism-related parameters
The Pearson correlation coefficients between ultrasound-esti-
mated liver fat content and other common anthropometric and 
biochemical parameters are given in Table 4. After adjustment 
for age, sex, and BMI, liver fat content estimated by ultrasound 
was positively associated with waist circumference, hip cir-
cumference, serum ALT, AST, triglycerides, Apo-E, and fast-
ing glucose levels and negatively associated with high-density 
lipoprotein cholesterol (HDL-C) levels.
reliability
There is “excellent” interobserver agreement for US hepatic/
renal ratio and US hepatic attenuation rate (ICC = 0.956 and 
ICC = 0.942, respectively). “Excellent” agreement between dif-
ferent ultrasound machines was also obtained for US hepatic/
renal ratio and US hepatic attenuation rate (ICC = 0.950 and 
ICC = 0.861, respectively). Bland and Altman analysis sug-
gested that if 95% of the difference were within the “limits 
of agreement” then this denoted good agreement between 
the two sets of measurements (Figure 3). According to the 
Bland–Altman method, the 95% limits of interobserver differ-
ence of US hepatic/renal ratio and US attenuation rate were 
−0.0989–0.1118 (−13.9–15.7% of total US hepatic/renal ratio 
range) and −0.0147–0.0161/cm/MHz (−19.2–21.1% of total 
US hepatic attenuation rate range), respectively. The 95% lim-
its of difference between different US machines were −0.1041–
0.1878  (−14.7–26.5%  of  range)  for  US  hepatic/renal  ratio, 
and −0.0185–0.0100/cm/MHz (−24.2–13.1% of range) for US 
attenuation rate, respectively. If we tolerate a difference smaller 
than 5% for liver fat content estimation, as shown by the inter-
rupted lines in Figure 4, 21 (91.3%) and 18 (69.2%) patients 
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Figure 2  (a) Linear correlation between liver fat contents by [1H]-MRS 
and (a) US hepatic/renal ratio (r = 0.884, P < 0.001) and (b) US hepatic 
attenuation rate (r = 0.711, P < 0.001).
table 2  Prediction models for hepatic fat content by [1h]-Mrs using anthropometric and ultrasound quantitative parametersa
Modela
B ± s.e.
Model P value Model adj. R2 RMSE
US hepatic/ 
renal ratio
US hepatic attenuation 
rate (MHz−1 cm−1) Constant
Hepatic fat  
content (%)
1 73.624 ± 3.482 — −35.808 ± 2.705 <0.001 78.0% 6.19
2 62.592 ± 4.615 168.076 ± 48.538 −27.863 ± 3.463 <0.001 79.8% 5.93
B, expected change in hepatic fat content per unit increase in the covariate; RMSE, root mean squared error; US, ultrasound.
aModel: candidate predictors included for analysis were age, gender, BMI, weight, waist circumference, waist-to-hip ratio, US hepatic/renal ratio, and US hepatic 
attenuation rate. Skewed variables were log transformed to normal distribution before linear regression analysis.obesity | VOLUME 20 NUMBER 2 | fEBRUaRy 2012  449
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would have the difference of calculated liver fat contents from 
different operators or different US machines within the range 
of ± 5% liver fat content (Figure 4).
dIscussIon
In this study, we found that computer-assisted US hepatic/
renal ratio and US hepatic attenuation rate from ordinary US 
hepatic and right kidney images were highly positively associ-
ated with liver fat content by [1H]-MRS. Combination of US 
hepatic/renal ratio and US hepatic attenuation rate could be 
used to simply and relative accurately estimate liver fat content, 
and our improved US quantitative method also showed higher 
sensitivity than traditional US qualitative method in detecting 
mild hepatic steatosis. As for the reliability of our improved 
US quantitative method for liver fat content, the reproducibil-
ity between different operators and different US machines was 
reasonably well after standardization by a tissue-mimicking 
phantom, as the difference of the US-estimated liver fat content 
between different operators and different ultrasound machines 
mostly fell in the range of ± 5% liver fat content.
Hepatic steatosis can be assessed by some characteristics on 
ultrasound images, including (i) hyperechogenity of liver tis-
sue (“bright liver”) as often compared to hypoechogenity of 
the kidney cortex, (ii) fall of echo amplitude with depth (pos-
terior beam attenuation), (iii) fine, tightly packed echoes, (iv) 
loss of echoes from the walls of the portal veins (20). However, 
these criteria are qualitative, so the traditional US diagnosis of 
hepatic steatosis was highly depended on the subjective inter-
pretation of the examiner, which can lead to limitation of the 
method reproducibility, and not least to diagnostic errors. In 
contrast, the computer-aided measurement of US H/R ratio 
and US hepatic echo-intensity attenuation rate realized the 
objective quantification of US image characteristics of hepatic 
steatosis and showed enormous advantages over traditional 
qualitative  US.  Using  the  ultrasound  quantitative  parame-
ters, we were able to identify the minimal “bright liver echo” 
changes on ultrasound images, which were impossible to dis-
tinguish by naked eyes. Thus, the low sensitivity of traditional 
US to detect mild steatosis (20) could be remarkably resolved 
by the US quantitative method, and in the current study we 
also confirmed the high sensitivity and specificity of US quan-
titative method in diagnosing mild hepatic steatosis. On the 
other hand, the ultrasound quantitative method is objective 
and less dependent on operators’ subjective impression, so it 
could overcome the subjective error of US examination results 
to a certain degree. The mean inter- and intraobserver agree-
ment rates for traditional US diagnosis of hepatic steatosis were 
72% and 76% (19). In comparison, the interobserver difference 
of US-quantified liver fat content in our current study is about 
± 5% liver fat content, which corresponds to 95.6% agreement 
rates for the qualitative diagnosis of hepatic steatosis. More 
importantly, our US quantitative method formulates a rela-
tive accurate quantification of the liver fat content, radically 
table 3  comparison of diagnostic performance between 
quantitative and qualitative ultrasound examinations
Diagnostic criteria
Fatty liver diagnosed by [1H]-MRS
Sensitivity   
(%)
Specificity   
(%) PPV(%) NPV(%)
All participants
  Quantitative  
  ultrasound  
  (estimated LFC ≥9.15%)
95.1 100 100 82.2
  Qualitative ultrasound 82.5 83.3 92.5 52.6
Participants with [1H]-MRS LFC <15%
  Quantitative ultrasound  
  (estimated LFC ≥9.15%)
82.6 100 100 85.7
  Qualitative ultrasound 47.8 83.3 73.3 62.5
LFC, liver fat content; NPV, negative predictive value; PPV, positive predictive value.
table 4  correlation of hepatic fat content by improved us 
with anthropometric, biochemical, and ultrasonic parameters 
in 127 subjects
Variables
Ultrasound liver  
fat content
Ultrasound 
hepatic fat 
content (age, sex, 
and BMI adjusted)
r P r P
Agea −0.157 0.077 — —
BMI 0.293 0.001 — —
Sex −0.113 0.207 — —
Weight 0.304 0.001 0.182 0.101
Height 0.178 0.056 0.182 0.101
Waist circumference 0.349 <0.001 0.347 0.001
Hip circumference 0.323 <0.001 0.226 0.042
Waist-to-hip ratio 0.291 0.002 0.204 0.065
SBP −0.007 0.944 −0.164 0.142
DBP 0.177 0.072 −0.020 0.859
ALTa 0.426 <0.001 0.372 0.001
ASTa 0.314 0.001 0.281 0.011
ALP 0.075 0.427 −0.115 0.303
γ-GTa 0.192 0.039 0.143 0.200
Triglyceridesa 0.403 <0.001 0.437 <0.001
Cholesterol 0.018 0.847 0.126 0.258
HDL cholesterol −0.322 0.001 −0.253 0.022
LDL cholesterol −0.097 0.306 −0.037 0.740
Apo-A −0.203 0.039 −0.138 0.215
Apo-B 0.194 0.049 0.204 0.066
Apo-Ea 0.302 0.003 0.333 0.002
Uric acid 0.191 0.045 0.159 0.154
Fasting glucosea 0.213 0.023 0.216 0.050
2-h postload glucose 0.209 0.033 0.205 0.065
[1H]-MRS hepatic fat 
content
0.895 <0.001 0.892 <0.001
HDL, high-density lipoprotein; LDL, low-density lipoprotein; US,ultrasonography.
aVariables were significantly skewed and log transformed to normal distribution 
when taken into Pearson correlation analysis.450  VOLUME 20 NUMBER 2 | fEBRUaRy 2012 | www.obesityjournal.org
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changes the qualitative nature of traditional US, and provides 
an ideal tool for quantification of liver fat content in large-
scale clinical studies and determination of treatment efficacy 
for hepatic steatosis. Therefore, the ultrasound quantitative 
method for liver fat content based on the combination of US 
quantitative parameters might be clinically valuable as an easy 
and relative accurate method to diagnose hepatic steatosis.
On the basis of the previous attempts on ultrasound quan-
tification of liver fat content (22–24), we further improved 
the US quantitative method by taking the difference among 
different ultrasound machines into consideration and intro-
duced a standardization procedure for the US image analysis. 
It is noticeable that the original US quantitative parameters 
measured with different ultrasound machines might vary tre-
mendously. The original hepatic/renal ratio ranged from 0.88 
to 2.17 (mean 1.39) in our study, while the US hepatic/renal 
ratios reported previously were 1.1–10.8 (mean 2.5 (23)) 
and 0.88–3.78 (mean 1.65 (22)), respectively. The great dis-
crepancy might be caused by the different postprocess when 
ultrasound scanner automatically translates echo amplitude 
values to the brightness on the US images. Different US 
machines have different forms of adaptive contrast or texture 
enhancement (31,32), so the initial US quantitative param-
eters from different US machines vary greatly, and this badly 
restricts its practicality and application forecast. To adjust 
for the difference among ultrasound devices, we introduced 
a tissue-mimicking phantom for standardization in the cur-
rent study, and the standardization procedure remarkably 
improved the comparability of US quantitative parameters 
among different US machines and increased the application 
and extension value of the ultrasound quantitative method 
for liver fat content.
Our study also showed that the optimal US-estimated liver 
fat content cutoff of 9.15% yielded very high sensitivity (95.1%) 
and specificity (100%), enabling us to attain good positive 
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Figure 3  Bland–Altman analysis for agreement of US quantitative parameters between measurements with different ultrasound machines (a,b) 
and by different operators (c,d). (a) measurement of US hepatic/renal ratio from GE Vivid7 US machine minus measurement from GE Logiq P5 
US machine; (b) measurement of US hepatic attenuation rate from GE Vivid7 US machine minus measurement from GE Logiq P5 machine; 
(c) measurement of US hepatic/renal ratio by operator 1 minus measurement by operator 2; and (d) measurement of US hepatic attenuation rate by 
operator 1 minus measurement by operator 2. LP5, Logiq P5.
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Figure 4  Bland–Altman analysis for agreement of liver fat content 
estimated with US quantitative parameters measured from (a) different 
ultrasound machines and (b) different operators. In a, 18 of 26 (69.2%) 
points fall within the range of ± 5% liver fat content; in b, 21 of 23 
(91.3%) points fall within the range of ± 5% liver fat content.obesity | VOLUME 20 NUMBER 2 | fEBRUaRy 2012  451
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predictive value (PPV) and negative predictive value (NPV) 
(100% and 82.2%, respectively) for the diagnosis of hepatic 
steatosis. Noticeably, the cutoff value for US-estimated liver 
fat content to diagnose hepatic steatosis is higher than that of 
[1H]-MRS. This result was explicable if we noticed that the liver 
fat content estimated by US was actually not strictly linearly 
related to [1H]-MRS liver fat content. When liver fat content 
by [1H]-MRS was between 5% and 40%, the US-estimated liver 
fat content agreed well with the liver fat content by [1H]-MRS. 
However, when the liver fat content by [1H]-MRS decreased 
approximately below 5%, the US-estimated liver fat content 
showed a steep decline from 5%–10% to 0%, and when the 
liver fat content increased over 40%, the US-estimated liver fat 
content tended to reach a platform. Therefore, the US hepatic 
fat quantification method might slightly overestimate real 
liver fat content when the liver fat content is near 5%, and the 
US-estimated liver fat content cutoff value for hepatic stea-
tosis was also higher than that of [1H]-MRS correspondingly 
(Supplementary Figure S2 online). Even though it was still 
an approximate estimation of liver fat content, the US quanti-
tative method is undoubtedly an advance in imaging diagno-
sis of hepatic steatosis. Because the US quantitative method 
is easy for operation, sensitive in detection of mild hepatic 
steatosis, and relatively accurate in reflecting the severity of 
hepatic steatosis, it is especially suitable for large-scale quan-
titative study on hepatic steatosis and clinical trials on the 
follow-up and determination of treatment efficacy for hepatic 
steatosis.
One limitation of our study is that spectroscopy, rather than 
histologic examination, was used as the reference. Pathologic 
examination of biopsied specimens from the liver remains 
the criterion standard in current clinical practice to establish 
the diagnosis of steatosis. However, liver biopsy is an invasive 
procedure with a morbidity rate of 3% and a mortality rate of 
0.03% (33). It has been demonstrated that histology correlates 
well with [1H]-MRS hepatic triglyceride content (15). Several 
clinical  trials  (34,35)  on  NAFLD  have  used  spectroscopic 
magnetic resonance as an outcome measure. Therefore, spec-
troscopy may be a more appropriate reference standard than 
histology in accurately assessing fat content.
In summary, our current improved US quantitative method 
integrated the merits of previous studies on ultrasound liver 
fat quantification, established a standardization procedure for 
measurement of US quantitative parameters, and provided a 
mathematical algorithm for liver fat content estimation with the 
US quantitative parameters. Further analysis on the validity of 
the improved US quantitative method confirmed the accuracy, 
reproducibility, and popularization value of this method, so this 
improved ultrasound quantitative method could be considered 
as a simple, relative accurate, reproducible, and low-cost ana-
lytic tool in the clinical evaluation of hepatic steatosis.
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